CRISPR Screens Detect Predictors of Myeloma Drug Responsiveness

Using CRISPR-Cas 9 screens, researchers were able to identify genetic determinants of response and resistance to commonly used drugs to treat multiple myeloma (MM). This study was published in Blood Advances. “While the genetic landscape of relapsed/[refractory] MM has been elucidated, the causal relationship between relapse-specific gene mutations and the sensitivity to a given drug … Continue reading CRISPR Screens Detect Predictors of Myeloma Drug Responsiveness